DE69027021D1 - Quinazolin-3-alkancarbonsäurederivat und salz und deren herstellung - Google Patents

Quinazolin-3-alkancarbonsäurederivat und salz und deren herstellung

Info

Publication number
DE69027021D1
DE69027021D1 DE69027021T DE69027021T DE69027021D1 DE 69027021 D1 DE69027021 D1 DE 69027021D1 DE 69027021 T DE69027021 T DE 69027021T DE 69027021 T DE69027021 T DE 69027021T DE 69027021 D1 DE69027021 D1 DE 69027021D1
Authority
DE
Germany
Prior art keywords
alkancarboxylic
quinazolin
derivative
salt
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69027021T
Other languages
English (en)
Other versions
DE69027021T2 (de
Inventor
Shizuyoshi Fujimori
Michiro Ohnota
Yoshihiro Hirata
Koji Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of DE69027021D1 publication Critical patent/DE69027021D1/de
Application granted granted Critical
Publication of DE69027021T2 publication Critical patent/DE69027021T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69027021T 1989-12-11 1990-12-10 Quinazolin-3-alkancarbonsäurederivat und salz und deren herstellung Expired - Fee Related DE69027021T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1321097A JPH0747582B2 (ja) 1989-12-11 1989-12-11 キナゾリン―３―アルカン酸誘導体とその塩およびその製造法
PCT/JP1990/001600 WO1991009024A1 (fr) 1989-12-11 1990-12-10 Derive de l'acide quinazoline-3-alcanoique, sels derives de ce compose et sa production

Publications (2)

Publication Number Publication Date
DE69027021D1 true DE69027021D1 (de) 1996-06-20
DE69027021T2 DE69027021T2 (de) 1997-01-02

Family

ID=18128787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027021T Expired - Fee Related DE69027021T2 (de) 1989-12-11 1990-12-10 Quinazolin-3-alkancarbonsäurederivat und salz und deren herstellung

Country Status (10)

Country Link
US (1) US5234928A (de)
EP (1) EP0456835B1 (de)
JP (1) JPH0747582B2 (de)
KR (1) KR960012196B1 (de)
AU (1) AU640194B2 (de)
CA (1) CA2046603A1 (de)
DE (1) DE69027021T2 (de)
ES (1) ES2087991T3 (de)
HU (1) HU207999B (de)
WO (1) WO1991009024A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US6448269B1 (en) 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
DE4341665A1 (de) * 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
US5994542A (en) * 1995-11-14 1999-11-30 Sumitomo Chemical Company, Limited Process for producing 1-substituted tetrahydroquinazolines
CA2190236C (en) * 1995-11-14 2000-01-25 Shinji Nishii Process for producing 1-substituted tetrahydroquinazolines
DE19724983A1 (de) * 1997-06-13 1998-12-17 Basf Ag Verfahren zur Herstellung von Chinazolindionen an fester Phase und ihre Verwendung
BR0010402A (pt) * 1999-03-09 2002-01-08 Fujisawa Pharmaceutical Co Processo para preparação de derivados de quinazolina
US6429214B1 (en) 1999-07-21 2002-08-06 Wyeth Bicyclic antagonists selective for the αvβ3 integrin
AU2003302893A1 (en) 2002-12-06 2004-06-30 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
EP1583747A2 (de) * 2002-12-31 2005-10-12 Vertex Pharmaceuticals Incorporated Phosphatase inhibitoren
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
JPWO2008133155A1 (ja) 2007-04-19 2010-07-22 アステラス製薬株式会社 二環式ヘテロ環化合物
EP2188277B1 (de) * 2007-08-16 2012-11-21 Boehringer Ingelheim International GmbH Chinazolindionchymasehemmer
AU2014262546B2 (en) 2013-05-10 2018-11-08 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN105358154A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
BR112015028214A2 (pt) * 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
CN104119344B (zh) * 2014-05-30 2017-06-06 上海天慈生物谷生物工程有限公司 一种制备6,7‑二氯代‑1,5‑二氢咪唑并[2,1‑b]喹唑啉‑2‑(3H)‑酮的方法
CN115785004A (zh) * 2022-11-30 2023-03-14 盐城工学院 一种羧基取代的喹喔啉酮衍生物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE277687C (de) * 1911-03-11 1914-09-04 Stanzwerk Oberscheden Juenemann & Co Verfahren und vorrichtung zum Sterilisieren von Milch
JPS5795966A (en) * 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
US4556739A (en) * 1983-09-29 1985-12-03 Ortho Pharmaceutical Corporation 3,4-Dialkoxy-2-alkylcarbonyl analino compounds
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤

Also Published As

Publication number Publication date
KR920701174A (ko) 1992-08-11
KR960012196B1 (ko) 1996-09-16
JPH03181469A (ja) 1991-08-07
AU6890591A (en) 1991-07-18
JPH0747582B2 (ja) 1995-05-24
WO1991009024A1 (fr) 1991-06-27
AU640194B2 (en) 1993-08-19
EP0456835A1 (de) 1991-11-21
CA2046603A1 (en) 1991-06-12
ES2087991T3 (es) 1996-08-01
US5234928A (en) 1993-08-10
EP0456835B1 (de) 1996-05-15
DE69027021T2 (de) 1997-01-02
HUT58304A (en) 1992-02-28
HU207999B (en) 1993-07-28
EP0456835A4 (en) 1992-06-03

Similar Documents

Publication Publication Date Title
DE69027021D1 (de) Quinazolin-3-alkancarbonsäurederivat und salz und deren herstellung
DE68924026D1 (de) Biosensor und dessen herstellung.
DE3579888D1 (de) Carbapenemverbindungen und deren herstellung.
DE3782315D1 (de) Absorbierende produkte und deren herstellung.
DE58906076D1 (de) Benzophenonderivate und deren Herstellung.
DE69226183D1 (de) Mit fluessigkeiten behandelte polytetrafluroaethylenprodukte und ihre herstellung
DE3878340D1 (de) Kristalliner l-carnosin-zink-komplex und dessen herstellung.
DE68903512D1 (de) Korrosionshemmendes pigment und dessen herstellung.
DE3689191D1 (de) Gereinigtes protein mit angiogenischer wirkung und dessen herstellung.
DE3676671D1 (de) Askorbat-2-polyphosphatester und deren herstellung.
HU913050D0 (en) 1,3-benzoxasine derivatives, production and application thereof
DE69106630D1 (de) Wässerige kosmetische Zusammensetzung und dessen Herstellungsverfahren.
DE69023227D1 (de) Fluorpolymere und deren herstellung.
ATE97424T1 (de) Modifizierte polydextrose und deren herstellung.
FI885488A (fi) 2,2-difluorisyklopropyylietaanijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö tuholaisten torjunta-aineina
IT8848259A0 (it) 1,4-diidropiridine, loro procedimento di preparazione e loro applicazione come medicamenti
DE59006688D1 (de) Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung.
DE3673587D1 (de) Magnetronanode und deren herstellung.
DE69206893D1 (de) Nucleosidderivate und deren Herstellung
DE69010924D1 (de) Antibiotikum L53-18A und dessen Herstellung.
DE3682882D1 (de) Menschliches immunoglobulin-g-fc-region-protein und dessen herstellung.
DE69329749D1 (de) Cycloolefincopolymer-zusammensetzung und deren herstellung
ATA280489A (de) Neue adenosin-derivate, deren herstellung und verwendung
DE3674789D1 (de) Balken und dessen herstellung.
DE69109675D1 (de) Geflechte und dessen herstellungsverfahren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee